Sees net profit $4M-$8M. “The SBC Medical Group deal is our biggest Go IPO deal to date, amassing a gross total of $17.9 million in total top line revenue for HeartCore,” said CEO Sumitaka Kanno Yamamoto. “Our team played a vital role in fostering the go public process for our treasured client, and we are very much looking forward to the progress and continued success SBC will create as a publicly traded company on the Nasdaq. Furthermore, we are very encouraged by our forecasted financials for Q3 2024, as HeartCore is slated to have its strongest quarter in corporate history. Relative to last year’s revenue for the first nine-months ended September 30, 2023, of $18.5 million, we anticipate generating between $28.1 million and $32.1 million in revenue for the nine months ended September 30, 2024, with a significant profit. We expect this year will be HeartCore’s strongest by far, and we continue to stay laser focused on providing value for our Go IPO clients, in addition to our enterprise software clients.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HTCR:
- HeartCore’s Go IPO Client, SBC Medical Group, Begins Trading on the Nasdaq Stock Exchange
- HeartCore to Present at the H.C. Wainwright 26th Annual Global Investment Conference on September 11, 2024
- HeartCore Enterprises Unveils 2024 Revenue Projections
- HeartCore Enterprises reports Q2 EPS (9c) vs (4c) last year
- HeartCore to Present at the 2024 Gateway Conference on September 4 at 10:30 a.m. Pacific Time